An observational study in Type 1 Diabetes, sponsored by Sanofi. Recruiting at 1 site in United States. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Sanofi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is one of 6 that started in 2025, is one of 6 observational ones, and was the 65th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Germany, Israel and 1 more country
Sanofi · Sites in Belgium, France, Germany and 3 more countries
Sanofi · Sites in Kuwait, Saudi Arabia, United Arab Emirates
Ages 18 mo–18 yrs · Healthy volunteers
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
Sanofi · Sites in United States
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 8 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 6 · Phase 3 20 · Phase 4 14
First in 2001; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 86 across the 60 interventional studies, 194 across the 6 observational. Of the 57 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
4 of the studies in Diabetes Mellitus, Type 1 by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
| NCT06812988SanofiTreatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | 2027-04-29 |
| NCT07038473SanofiEarly Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF) | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an observational, longitudinal, non-interventional real-world study in the United States. The study is meant to describe the experience of participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab and the experience of participants with stage 2 type 1 diabetes who have not been infused with teplizumab, and to compare descriptively the experiences of the two groups.
Primary Objective:
- To characterize health related quality of life, diabetes-related anxiety, diabetes-related burden, and ease of diabetes management, and how participants feel, form and function in those who infused and those who did not infuse with teplizumab
Secondary Objectives:
Each participant is expected to participate in the study from the time of their enrollment through the last data delivery, which is estimated to occur five years after the first participant is enrolled.
Individuals with a history of Stage 2 T1D (documented in medical records) and infused with teplizumab or not infused with teplizumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Failure to complete the baseline survey
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab at the time of enrollment
Drug: Teplizumab
Participants with stage 2 type 1 diabetes who have not been infused with teplizumab at the time of enrollment
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Also known as: TZIELD
Change in participant and caregiver-reported outcomes from survey responses: ease of diabetes management questions
Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years
Change in participant and caregiver-reported outcomes from survey responses: Psychological well-being World Health Organization-5 (WHO-5)
Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years
Change in participant and caregiver-reported outcomes from survey responses: State-Trait Anxiety Inventory (STAI)
Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years
Change in participant and caregiver-reported outcomes from survey responses: Type 1 Diabetes Distress Assessment System-Core Scale (T1-DDAS CORE)
Time frame: From baseline, repeated every 6 months, up to end of study, approximately 5 years
Change in participant and caregiver-reported outcomes from survey responses: Diabetes constraints scale
Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years
Sociodemographic screening characteristics
Time frame: At enrollment
Sociodemographic medical history characteristics
Time frame: At enrollment
Sociodemographic diabetes management characteristics
Time frame: At enrollment
Changes in characteristics of participants: monitoring practices (e.g. continuous glucose monitor, self-monitoring blood glucose, blood drawn by clinician) across type 1 diabetes stages
Time frame: From enrollment up to study end, approximately 5 years
Changes in characteristics of participants: medical history across type 1 diabetes stages
Time frame: From enrollment up to study end, approximately 5 years
Time from index date to the diagnosis of stage 3 type 1 diabetes
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: HbA1c
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: blood glucose
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: post prandial glucose
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: c-peptide
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: time in range in participants with glucose monitor data
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: time above range in participants with glucose monitor data
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: time below range in participants with glucose monitor data
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: glucose variability percent in participants with glucose monitor data
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose parameters: percent coefficient of variation in participants with glucose monitor data
Time frame: From baseline up to end of study, approximately 5 years
Changes in glucose paremeters: glucose management indicator in participants with glucose monitor data
Time frame: From baseline up to end of study, approximately 5 years
Number of complications (including micro- and macrovascular occurrences and hypoglycemia occurrences)
Time frame: From baseline up to end of study, approximately 5 years
The frequency of glycemic vs. autoantibody testing related to stage 2 type 1 diabetes diagnosis
Time frame: At enrollment
The sequence (first or second) of glycemic testing vs. autoantibody testing related to stage 2 type 1 diabetes diagnosis
Sequence describes if glycemic testing or autoantibody testing took place first in stage 2 type 1 diabetes diagnosis
Time frame: At enrollment
The frequency of misclassification with type 2 diabetes
Time frame: At enrollment
The time between misclassification with type 2 diabetes and autoantibody testing
Time frame: At enrollment
The time between misclassification with type 2 diabetes and the correct diagnosis of stage 2 type 1 diabetes
Time frame: At enrollment
Time from index date to the diagnosis of stage 3 type 1 diabetes for those misclassified with type 2 diabetes where diagnosis is confirmed by HbA1c and/or glycemic measures
Time frame: From baseline up to end of study, approximately 5 years
Proportion (%) of participants using home glycemic monitoring assessments (Continuous Glucose Monitor, self-monitoring blood glucose, urine glucose monitoring) vs in-clinic assessments (HbA1c, fasting blood glucose, c-peptide)
Time frame: From baseline up to end of study, approximately 5 years
Proportion (%) of participants using insulin characterized by insulin dosing, type, regimen, and mode of administration
Time frame: From baseline up to end of study, approximately 5 years
Annualized rate of hospitalizations due to type 1 diabetes complications
Time frame: From baseline up to end of study, approximately 5 years
Annualized rate of emergency room visits due to type 1 diabetes complications
Time frame: From baseline up to end of study, approximately 5 years
Annualized rate of specialist (including endocrinologist) visits
Time frame: From baseline up to end of study, approximately 5 years
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 61 months after the start.
Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 61 months is above that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.